BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 26346408)

  • 1. Voriconazole therapeutic drug monitoring: results of a prematurely discontinued randomized multicenter trial.
    Neofytos D; Ostrander D; Shoham S; Laverdiere M; Hiemenz J; Nguyen H; Clarke W; Brass L; Lu N; Marr KA
    Transpl Infect Dis; 2015 Dec; 17(6):831-7. PubMed ID: 26346408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical usefulness of therapeutic drug monitoring of voriconazole in a university hospital.
    Cabral-Galeano E; Ruiz-Camps I; Len-Abad O; Pou-Clavé L; Sordé-Masip R; Meije-Castillo Y; Blanco-Grau A; Barba-Suñol P; Monforte-Torres V; Román-Broto A; Pahissa-Berga A; Gavaldà-Santapau J
    Enferm Infecc Microbiol Clin; 2015 May; 33(5):298-302. PubMed ID: 25459191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial.
    Park WB; Kim NH; Kim KH; Lee SH; Nam WS; Yoon SH; Song KH; Choe PG; Kim NJ; Jang IJ; Oh MD; Yu KS
    Clin Infect Dis; 2012 Oct; 55(8):1080-7. PubMed ID: 22761409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Voriconazole therapeutic drug monitoring in critically ill patients improves efficacy and safety of antifungal therapy.
    Li H; Li M; Yan J; Gao L; Zhou L; Wang Y; Li Q; Wang J; Chen T; Wang T; Zheng J; Qiang W; Zhang Y; Shi Q
    Basic Clin Pharmacol Toxicol; 2020 Dec; 127(6):495-504. PubMed ID: 32639669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of plasma unbound fraction of voriconazole in patients treated with a prophylactic or a curative treatment.
    Florent A; Gandia P; Seraissol P; Chatelut E; Houin G
    Ther Drug Monit; 2014 Dec; 36(6):752-8. PubMed ID: 24819971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Therapeutic Drug Monitoring and Cytochrome P450 2C19 Genotyping on Clinical Outcomes of Voriconazole: A Systematic Review.
    Lee J; Ng P; Hamandi B; Husain S; Lefebvre MJ; Battistella M
    Ann Pharmacother; 2021 Apr; 55(4):509-529. PubMed ID: 32772568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinician ordering practices for voriconazole therapeutic drug monitoring: experiences of a referral laboratory.
    Miyakis S; van Hal SJ; Solvag CJ; Ray J; Marriott D
    Ther Drug Monit; 2010 Oct; 32(5):661-4. PubMed ID: 20720520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic drug monitoring-guided treatment versus standard dosing of voriconazole for invasive aspergillosis in haematological patients: a multicentre, prospective, cluster randomised, crossover clinical trial.
    Veringa A; Brüggemann RJ; Span LFR; Biemond BJ; de Boer MGJ; van den Heuvel ER; Klein SK; Kraemer D; Minnema MC; Prakken NHJ; Rijnders BJA; Swen JJ; Verweij PE; Wondergem MJ; Ypma PF; Blijlevens N; Kosterink JGW; van der Werf TS; Alffenaar JC;
    Int J Antimicrob Agents; 2023 Feb; 61(2):106711. PubMed ID: 36642232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Voriconazole and posaconazole therapeutic drug monitoring: a retrospective study.
    Yi WM; Schoeppler KE; Jaeger J; Mueller SW; MacLaren R; Fish DN; Kiser TH
    Ann Clin Microbiol Antimicrob; 2017 Sep; 16(1):60. PubMed ID: 28893246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing Azole Plasma Trough Levels in Lung Transplant Recipients: Percentage of Therapeutic Levels and Intrapatient Variability.
    Stelzer D; Weber A; Ihle F; Matthes S; Ceelen F; Zimmermann G; Kneidinger N; Schramm R; Winter H; Zoller M; Vogeser M; Behr J; Neurohr C
    Ther Drug Monit; 2017 Apr; 39(2):93-101. PubMed ID: 28282366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Optimized Voriconazole Dosing Strategy to Achieve Therapeutic Serum Concentrations in Children Younger than 2 Years Old.
    Zembles TN; Thompson NE; Havens PL; Kaufman BA; Huppler AR
    Pharmacotherapy; 2016 Oct; 36(10):1102-1108. PubMed ID: 27548272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of sustained high plasma trough concentration of voriconazole with the incidence of hepatotoxicity.
    Suzuki Y; Tokimatsu I; Sato Y; Kawasaki K; Sato Y; Goto T; Hashinaga K; Itoh H; Hiramatsu K; Kadota J
    Clin Chim Acta; 2013 Sep; 424():119-22. PubMed ID: 23747486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of voriconazole therapeutic drug monitoring: a meta-analysis.
    Luong ML; Al-Dabbagh M; Groll AH; Racil Z; Nannya Y; Mitsani D; Husain S
    J Antimicrob Chemother; 2016 Jul; 71(7):1786-99. PubMed ID: 27165788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Practice Guideline for the Therapeutic Drug Monitoring of Voriconazole in Non-Asian and Asian Adult Patients: Consensus Review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.
    Takesue Y; Hanai Y; Oda K; Hamada Y; Ueda T; Mayumi T; Matsumoto K; Fujii S; Takahashi Y; Miyazaki Y; Kimura T;
    Clin Ther; 2022 Dec; 44(12):1604-1623. PubMed ID: 36424314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different effects of lansoprazole and rabeprazole on the plasma voriconazole trough levels in allogeneic hematopoietic cell transplant recipients.
    Yasu T; Konuma T; Kato S; Kurokawa Y; Takahashi S; Tojo A
    Ann Hematol; 2016 Oct; 95(11):1845-51. PubMed ID: 27535751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Voriconazole concentrations and outcome of invasive fungal infections.
    Miyakis S; van Hal SJ; Ray J; Marriott D
    Clin Microbiol Infect; 2010 Jul; 16(7):927-33. PubMed ID: 19845698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic drug monitoring of voriconazole in Japanese patients: analysis based on clinical practice data.
    Matsumoto K; Abematsu K; Shigemi A; Kanazawa N; Watanabe E; Yokoyama Y; Ikawa K; Morikawa N; Takeda Y
    J Chemother; 2016 Jun; 28(3):198-202. PubMed ID: 26187373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of antifungal stewardship using therapeutic drug monitoring in voriconazole therapy on the prevention and control of hepatotoxicity and visual symptoms: A multicentre study conducted in Japan.
    Hamada Y; Ueda T; Miyazaki Y; Nakajima K; Fukunaga K; Miyazaki T; Nakada-Motokawa N; Nagao M; Kawamura H; Shigemi A; Ebihara F; Kimura T; Ikegame K; Uchino M; Ikeuchi H; Takesue Y
    Mycoses; 2020 Aug; 63(8):779-786. PubMed ID: 32510723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience.
    Racil Z; Winterova J; Kouba M; Zak P; Malaskova L; Buresova L; Toskova M; Lengerova M; Kocmanova I; Weinbergerova B; Timilsina S; Rolencova M; Cetkovsky P; Mayer J
    Mycoses; 2012 Nov; 55(6):483-92. PubMed ID: 22429709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a therapeutic drug-monitoring algorithm for outpatients receiving voriconazole: A multicentre retrospective study.
    Kato H; Umemura T; Hagihara M; Shiota A; Asai N; Hamada Y; Mikamo H; Iwamoto T
    Br J Clin Pharmacol; 2024 May; 90(5):1222-1230. PubMed ID: 38320604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.